{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:37:48Z","timestamp":1791049068071,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Myasthenia gravis (MG) is an autoimmune disease causing motor fatiguability. The impact of MG on quality of life (QoL) is incompletely studied. Here, we explore the impact of disease activity on QoL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the Swedish nationwide MG registry, 150 MG cases with concomitant EQ-5D-3L and MG\u2013ADL, QMG and\/or MG\u2013QoL-15 scores were identified. An EQ-5D score was derived from EQ-5D-3L using the UK time trade-off tariff and compared to a Swedish reference population. Longitudinal analysis assessing the impact of change in MG\u2013ADL on QoL was performed on data from the randomized-controlled RINOMAX trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>EQ-5D score was negatively correlated with MG\u2013ADL, QMG and MG\u2013QoL-15 (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.48,\u2009\u2212\u20090.33, and\u2009\u2212\u20090.66, respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The usual activities dimension deviated most from reference population, although all dimensions were significantly impacted. Lower EQ-5D score was observed already at low-to-moderate disease activity, MG\u2013ADL 3\u20135 points, compared to reference (0.71 [SD 0.23] vs. 0.81 [SD 0.04]; <jats:italic>p<\/jats:italic>\u2009=\u20090.01), and was further decreased with higher disease activity. Longitudinal analyses revealed a significant decrease of EQ-5D score per point increase in MG\u2013ADL (<jats:italic>\u03b2<\/jats:italic> \u20130.050 [95%CI \u20130.077, \u20130.023]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Most impact on EQ-5D score was observed by limb and respiratory items (limb <jats:italic>\u03b2<\/jats:italic>\u2009\u2212\u20090.17 [95%CI\u2009\u2212\u20090.26,\u2009\u2212\u20090.071]; <jats:italic>p<\/jats:italic>\u2009=\u20090.001, respiratory <jats:italic>\u03b2<\/jats:italic>\u2009\u2212\u20090.21 [95%CI\u2009\u2212\u20090.39,\u2009\u2212\u20090.031]; <jats:italic>p<\/jats:italic>\u2009=\u20090.022), while bulbar symptoms showed no effect on EQ-5D score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We observed a considerably decreased EQ-5D score already at low disease activity in MG patients, worsening with increasing disease activity. This indicates an unmet medical need that warrants improved treatment and care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13298-4","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T18:10:02Z","timestamp":1754590202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-0429","authenticated-orcid":false,"given":"Malin","family":"Petersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Schager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Brauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"5","key":"13298_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/joim.12310","volume":"277","author":"F Fang","year":"2015","unstructured":"Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE et al (2015) The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 277(5):594\u2013604","journal-title":"J Intern Med"},{"issue":"2","key":"13298_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149","journal-title":"Muscle Nerve"},{"key":"13298_CR3","doi-asserted-by":"crossref","unstructured":"Vissing J, Atula S, Savolainen M, Meht\u00e4l\u00e4 J, Mehkri L, Olesen TB, et al. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry. 2024 Mar 27 [cited 2024 Apr 1]. https:\/\/jnnp.bmj.com\/content\/early\/2024\/03\/27\/jnnp-2023-333097","DOI":"10.1136\/jnnp-2023-333097"},{"issue":"3","key":"13298_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","volume":"180","author":"E Salort-Campana","year":"2024","unstructured":"Salort-Campana E, Laforet P, de Pouvourville G, Crochard A, Chollet G, Nevoret C et al (2024) Epidemiology of myasthenia gravis in France: a retrospective claims database study (STAMINA). Rev Neurol 180(3):202\u2013210","journal-title":"Rev Neurol"},{"issue":"4","key":"13298_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J, Heidbrede T, Mahic M, Wilke T et al (2023) Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord 33(4):324\u2013333","journal-title":"Neuromuscul Disord"},{"key":"13298_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012604","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R et al (2021) Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000012604","journal-title":"Neurology"},{"issue":"4","key":"13298_CR7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s12325-023-02437-w","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Qi CZ, Phillips G, Iannazzo S, Janssen MF (2023) Association between myasthenia gravis-activities of daily living (MG-ADL) and EQ-5D-5L utility values: the additional effect of efgartigimod on utilities. Adv Ther 40(4):1818\u20131829","journal-title":"Adv Ther"},{"issue":"1","key":"13298_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","volume":"43","author":"TM Burns","year":"2011","unstructured":"Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, MG Composite and MG-OL15 Study Group (2011) The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43(1):14\u201318","journal-title":"Muscle Nerve"},{"issue":"1","key":"13298_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C et al (2023) Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open 13(1):e066445","journal-title":"BMJ Open"},{"issue":"473","key":"13298_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123493","volume":"7","author":"LK Andersen","year":"2025","unstructured":"Andersen LK, Petersen KG, Deurell EM, Lagoni A, Kaalund AB, Flensted IF et al (2025) EQ-5D-5L is a relevant tool for detecting patients with myasthenia gravis needing medical treatment. J Neurol Sci 7(473):123493","journal-title":"J Neurol Sci"},{"issue":"6","key":"13298_CR11","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J (2022) Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol 269(6):3086\u20133093","journal-title":"J Neurol"},{"issue":"4","key":"13298_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","volume":"20","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Xin H, L\u02bcItalien GJ, Harris LA, Cutter GR (2019) Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis 20(4):173\u2013181","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"13298_CR13","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L et al (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269(6):3050\u20133063","journal-title":"J Neurol"},{"key":"13298_CR14","doi-asserted-by":"publisher","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. (2020) Determinants of quality of life in myasthenia gravis patients. Front Neurol. Sep 23 [cited 2024 Oct 29];11. https:\/\/www.frontiersin.org\/journals\/neurology\/articles\/https:\/\/doi.org\/10.3389\/fneur.2020.553626\/full","DOI":"10.3389\/fneur.2020.553626\/full"},{"issue":"1","key":"13298_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH et al (2015) An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes 13(1):115","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"13298_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53\u201372","journal-title":"Health Policy"},{"issue":"1","key":"13298_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5(1):1\u201330","journal-title":"J Health Econ"},{"issue":"11","key":"13298_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA et al (2022) Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112","journal-title":"JAMA Neurol"},{"key":"13298_CR19","doi-asserted-by":"crossref","unstructured":"Devlin PDN, Parkin D, Janssen B. An Introduction to EQ-5D Instruments and Their Applications. In: Methods for Analysing and Reporting EQ-5D Data [Internet] [Internet]. Springer; 2020 [cited 2024 Oct 23]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565680\/","DOI":"10.1007\/978-3-030-47622-9_2"},{"key":"13298_CR20","unstructured":"EQ-5D-5L [Internet]. EuroQol. [cited 2024 Nov 18]. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/"},{"issue":"2","key":"13298_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11136-013-0496-4","volume":"23","author":"K Burstr\u00f6m","year":"2013","unstructured":"Burstr\u00f6m K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin L\u00c5 et al (2013) Swedish experience-based value sets for EQ-5D health states. Qual Life Res 23(2):431","journal-title":"Qual Life Res"},{"issue":"7","key":"13298_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621\u2013635","journal-title":"Qual Life Res"},{"key":"13298_CR23","unstructured":"Morton F, Nijjar JS. eq5d: Methods for Analysing \u2018EQ-5D\u2019 Data and Calculating \u2018EQ-5D\u2019 Index Scores. 2024 [cited 2024 Sep 17]. https:\/\/cran.r-project.org\/web\/packages\/eq5d\/index.html"},{"issue":"12","key":"13298_CR24","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95(12):e1617\u2013e1628","journal-title":"Neurology"},{"issue":"7","key":"13298_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131487","journal-title":"Neurology"},{"issue":"6","key":"13298_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6):630\u2013639","journal-title":"Muscle Nerve"},{"issue":"7","key":"13298_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"issue":"12","key":"13298_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"5","key":"13298_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395\u2013406","journal-title":"Lancet Neurol"},{"issue":"1","key":"13298_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan WW","year":"1998","unstructured":"Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia Gravis Scorea. Ann N Y Acad Sci 841(1):769\u2013772","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"13298_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","volume":"23","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H (2020) Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol 23(11):596382","journal-title":"Front Neurol"},{"issue":"10","key":"13298_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40273-023-01285-4","volume":"41","author":"M Falk Hvidberg","year":"2023","unstructured":"Falk Hvidberg M, Hern\u00e1ndez Alava M (2023) Catalogues of EQ-5D-3L health-related quality of life scores for 199 chronic conditions and health risks for use in the UK and the USA. Pharmacoeconomics 41(10):1287\u20131388","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"13298_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K (2021) The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther 10(2):1103\u20131125","journal-title":"Neurol Ther"},{"issue":"5","key":"13298_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068104","volume":"13","author":"S Berrih-Aknin","year":"2023","unstructured":"Berrih-Aknin S, Palace J, Meisel A, Claeys KG, Muppidi S, Sacc\u00e0 F et al (2023) Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG). BMJ Open 13(5):e068104","journal-title":"BMJ Open"},{"issue":"11","key":"13298_CR35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","volume":"48","author":"MA Sprangers","year":"1999","unstructured":"Sprangers MA, Schwartz CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48(11):1507\u20131515","journal-title":"Soc Sci Med"},{"issue":"1","key":"13298_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mus.23245","volume":"46","author":"TM Burns","year":"2012","unstructured":"Burns TM, Graham CD, Rose MR, Simmons Z (2012) Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve 46(1):9\u201325","journal-title":"Muscle Nerve"},{"issue":"3","key":"13298_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.13836","volume":"26","author":"C Barnett","year":"2019","unstructured":"Barnett C, Bril V, Bayoumi AM (2019) EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur J Neurol 26(3):452\u2013459","journal-title":"Eur J Neurol"},{"issue":"6","key":"13298_CR38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson AJ, Turner AJ (2020) A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics 38(6):575\u2013591","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"13298_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-018-0642-5","volume":"36","author":"I Buchholz","year":"2018","unstructured":"Buchholz I, Janssen MF, Kohlmann T, Feng YS (2018) A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics 36(6):645\u2013661","journal-title":"Pharmacoeconomics"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13298-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:35Z","timestamp":1760524535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13298-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13298"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13298-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anonymized data generated for the study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"MP and JW report no disclosures relevant to the manuscript. FB is an employee and stockholder of UCB, Copenhagen, Denmark. IS is an employee of UCB, Stockholm, Sweden. FP has received research grants from Denka, Janssen, Merck KGaA, Novartis, Pfizer and UCB unrelated to commercial products, and fees for serving on DMC in clinical trials with Lundbeck and Roche, and preparation of expert witness statement for Novartis. SB has received research grants from UCB and Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Stockholm regional ethics committee, Number 2016\/828\u201331 and 2016\/870\u201331. All participants gave oral consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}],"article-number":"562"}}